EVO Evotec SE ADR

Evotec SE's stock has begun to stabilize after a turbulent year marked by operational setbacks and governance issues. While the company still faces challenges in a capital-intensive industry, recent news suggests a focus on execution and stabilization, with analysts cautiously optimistic about its long-term prospects. Investors are now evaluating whether the bottom has been reached or if this is merely a temporary pause in a larger restructuring.

Evotec SE has issued a release according to Article 40, Section 1 of the WpHG, announcing a major holding notification from JPMorgan Chase & Co. JPMorgan Chase & Co. has crossed a threshold, now holding a total of 5.62% of voting rights in Evotec SE, up from 5.14% reported previously. This notification details the breakdown of voting rights attached to shares and instruments, with the date crossed being December 19, 2025.

Evotec (NASDAQ:EVO) gapped up in pre-market trading, opening at $3.10 after closing at $2.99, and was last trading at $3.0950 with 10,485 shares exchanging hands. Analyst opinions are mixed, with RBC reiterating an "Outperform" rating, while Wall Street Zen and Weiss Ratings issued "Sell" ratings, resulting in an overall "Hold" consensus and a price target of $7.00. The company exhibits healthy liquidity and modest leverage, and institutional investors like DCF Advisers LLC have significantly increased their stakes.

This article announces that Evotec SE has released a voting rights announcement in accordance with Article 40, Section 1 of the WpHG. JPMorgan Chase & Co. has notified of significant holdings in Evotec SE, crossing a threshold on December 17, 2025. The notification details JPMorgan's total positions, including voting rights attached to shares and through various financial instruments, and lists the controlled undertakings related to JPMorgan Chase & Co.

Wall Street Zen has upgraded Evotec (NASDAQ:EVO) to a "sell" rating, aligning with Weiss Ratings' recent "sell" call, while Royal Bank of Canada maintains an "outperform" rating. Evotec shares are trading near their yearly lows at $2.95, with some hedge funds increasing their positions, leading institutional investors to own about 5.81% of the stock. The consensus rating for the stock remains "Hold" with a price target of $7.00.

Evotec SE announced that its partner Bayer AG has initiated a Phase 2 clinical study for BAY 3401016, a potential treatment for Alport syndrome, a rare genetic kidney disease. This advancement triggers a milestone payment for Evotec from the 2016 multi-target research collaboration agreement. The study, named ASSESS, will evaluate the efficacy and safety of the monoclonal antibody in participants aged 18 to 45.